AB Science SA · EURONEXT:AB
AB Science SA — Technical Presentation (May 2021)
28 slides from AB Science SA's technical presentation, May 25, 2021
Slide 1: Masitinib in First Line Metastatic Castrate Resistant Prostate Cancer (mCRPC)
AB Science Webconference MASITINIB IN FIRST LINE METASTATIC CASTRATE RESISTANT PROSTATE CANCER (mCRPC) 25 May 2021
Slide 2: Disclaimer
Disclaimer This presentation, together with the material set forth herein, does not constitute an offer of securities for sale nor the solicitation of an offer to purchase securities in any jurisdiction. Distribution of such presentation in certain jurisdiction may constitute a breach of applicable
Slide 3: Expert Panel
EXPERT PANEL Stéphane Oudard, MD, PhD Professor of Oncology and Chief of the Oncology Clinical and Translational Research Unit at the Georges Pompidou Hospital in Paris, France. He is professor in Oncology at the René Descartes University, Paris, France. Theo M. de Reijke, MD, PhD, FEBU Associate Pr
Slide 4: Prostate cancer
Prostate cancer Metastatic prostate cancer is still an unmet medical need ❖ Docetaxel was registered in 2004 by FDA with a label for metastatic prostate cancer progressing after hormono-therapy ❖ There is no drug registered in combination with Docetaxel ❖ The median survival of patients will metasta
Slide 5: Masitinib Positioning in Prostate Cancer
Masitinib Positioning in Prostate Cancer Masitinib is positioned in combination with docetaxel as first-line treatment of mCRPC eligible to chemotherapy Stage of the desease Main Phase 3 Registered Drug1 Enzalutamide (Xtandi) High-risk non Metastatic Castration Resistant 1 Abiraterone (Zytiga) Prost
Slide 6: Masitinib Profile and Mechanism of Action
Masitinib Profile and Mechanism of Action Orally-administered kinase inhibitor selectively targeting mast cells and microglia Masitinib targets mast cells Kinase inhibition profile of masitinib • Masitinib is a selective inhibitor of c-Kit, Lyn, and Fyn kinases Cellular Target Molecular Target IC50
Slide 7: Scientific Rationale in Prostate Cancer
Scientific Rationale in Prostate Cancer Innate immune cells, in particular mast cells and macrophages, are critical components of the tumor microenvironment, promoting angiogenesis and tumor growth, and also contributing to tumorigenesis by suppression of the immune response ❖ The amount of mast cel
Slide 8: Masitinib has no direct tumor killer activity but shows efficacy on tumor growth
Scientific Rationale in Prostate Cancer Masitinib has no direct “tumor killer” general activity but has shown efficacy on tumor proliferation in vivo, mediated through the tumor micro-environment No direct effect on tumor cells in vitro… …but decreases tumor volume growth in vivo B16 Melanoma Lung C
Slide 9: Masitinib Clinical Development Plan in Prostate Cancer
Masitinib Clinical Development Plan in Prostate Cancer The development program prostate cancer is comprised of AB07004 proof of concept study, and AB12003 phase 3 study Primary Patient Phase Study code Design Population Dosing endpoint target Masitinib 9.0mg/kg/d + metastatic Hormone Docetaxel Prosp
Slide 10: AB07004 study results in Prostate Cancer
AB07004 study results in Prostate Cancer Proof of concept study supported the combination of masitinib with docetaxel in mRCPC Median OS estimation Lower bound of the Alpha set in the with median one-sided CI Treatment group protocol Kaplan Meier method (months) (months) Masitinib + Docetaxel 18.4 1
Slide 11: AB12003 – Study Design
AB12003 – Study Design Study AB12003 evaluated masitinib 6.0 mg/kg/day in combination with docetaxel versus docetaxel alone in first-line treatment of mCRPC Design: A prospective, multicenter, randomized, double blind, placebo-controlled, 2-parallel groups, phase 3 study Groups: ▪ Masitinib 6.0 mg/k
Slide 12: AB12003 – Primary Endpoint
AB12003 – Primary Endpoint The primary endpoint was PFS measured with PCWG2 definition, which is based on the earliest between radiographic progression, PSA progression, Pain progression, or death ❖ Primary endpoint : Progression Free Survival (PFS) as per PCWG2 Variable Assessment Radiographic prog
Slide 13: AB12003 – Sensitivity and Secondary Analyses
AB12003 – Sensitivity and Secondary Analyses Primary efficacy analysis was completed with sensitivity analyses of the primary endpoint and several secondary analyses PFS Sensitivity analyses Secondary analyses Sensitivity analyses were performed for primary analysis with: ▪ Progression Free Survival
Slide 14: AB12003 – Population Tested & Control of Alpha Risk
AB12003 – Population Tested & Control of Alpha Risk The study pre-specified the overall population and a targeted subgroup defined as patients with ALP ≤ 250 IU/ml at baseline ❖ The study tested the success of the primary endpoint in two populations ▪ Overall population ▪ Targeted subgroup of intere
Slide 15: AB12003 – Sample Size
AB12003 – Sample Size Primary analysis was based on 450 patients in the targeted subgroup and 712 patients in the overall population Sample Size Population Flow Chart Initial protocol plan ▪ 390 patients in Targeted sub-group Overall Population Targeted Subgroup ▪ 580 patients in the overall populat
Slide 16: AB12003 – Baseline Characteristics – Overall Population
AB12003 – Baseline Characteristics – Overall Population Baseline characteristics were balanced for age but possibly disbalanced in favor of the control arm for PSA and Chromogranin A Masitinib + Docetaxel Placebo + Docetaxel Masitinib + Docetaxel Placebo + Docetaxel ITT ITT (N = 356) (N = 358) (N =
Slide 17: AB12003 – Baseline Characteristics – Targeted Subgroup
AB12003 – Baseline Characteristics – Targeted Subgroup Baseline characteristics were balanced for age but possibly disbalanced in favor of the control arm for PSA and Chromogranin A Masitinib + Docetaxel Placebo + Docetaxel Masitinib + Docetaxel Placebo + Docetaxel ITT ITT (N = 226) (N = 225) (N = 2
Slide 18: AB12003 – PFS Primary analysis (ALP ≤ 250)
AB12003 – PFS Primary analysis (ALP ≤ 250) The study met its primary analysis in the pre-specified targeted subgroup (patients with ALP ≤ 250 IU/ml), demonstrating a statistically significant increase in PFS (p=0.0272) Analysis of Progression Free Survival (PFS) (Overall PFS) - Targeted sub-populati
Slide 19: AB12003 – Sensitivity analyses of Primary analysis (ALP ≤ 250)
AB12003 – Sensitivity analyses of Primary analysis (ALP ≤ 250) Sensitivity analysis of the primary endpoint were all consistent with a benefit ranging from 21% to 24% Sensitivity Analyses of the PFS PCWG2 - Targeted sub-population No. of Median Log Rank Hazard Ratio Analysis Treatment Patient Events
Slide 20: AB12003 – PFS Rate (ALP ≤ 250)
AB12003 – PFS Rate (ALP ≤ 250) The percentage of non-progressors was in favor of masitinib at all timepoints in the targeted subgroup Analysis of Progression Free Survival (PFS) (Overall PFS) - Targeted sub-population Non progression Month 6 Month 12 Month 18 Month 24 Month 30 Month 36 Month 42 Mont
Slide 21: AB12003 – PFS Analysis - Overall Population
AB12003 – PFS Analysis - Overall Population There was no PFS benefit in the overall population Analysis of Progression Free Survival (PFS) (Overall PFS) – Overall Population Percentage Log Rank Hazard Ratio Treatment Patients No. of Events Median [95% CI] censored p-value (95% CI) Masitinib 6.0 mg/k
Slide 22: AB12003 – PFS Sensitivity analyses on ALP
AB12003 – PFS Sensitivity analyses on ALP The lower the ALP level, the greater the masitinib treatment effect, in line with greater treatment effect expected in early metastatic phase Analysis of Progression Free Survival (PFS) (Overall PFS) based on ALP level ALP Percentage No. of Percentage Median
Slide 23: AB12003 – Overall Survival (ALP ≤ 250)
AB12003 – Overall Survival (ALP ≤ 250) There was not benefit on overall survival in the targeted subgroup Analysis of Overall Survival (OS) – Targeted sub-population Percentage Log Rank Hazard Ratio Treatment Patients No. of Events Median [95% CI] censored p-value (95% CI) Masitinib 6.0 mg/kg/day +
Slide 24: AB12003 – TTP Analysis on Overall Population
AB12003 – TTP Analysis on Overall Population In the overall population, there was a statistically significant increase in TTP (+4 months, p=0.0493), proving that masitinib is active against prostate metastases Analysis of Time to Radiographic Progression – Overall Population Percentage Log Rank Haza
Slide 25: AB12003 – Safety Overview
AB12003 – Safety Overview The safety of masitinib was consistent with its known tolerability profile Summary of Adverse Events Masitinib + Docetaxel Placebo + Docetaxel (N = 355) (N = 357) At least one AE 343 ( 96.6) 344 ( 96.4) Fatal AE 19 ( 5.4) 22 ( 6.2) At least one serious AE (non-fatal) 98 ( 2
Slide 26: Intellectual Property
Intellectual Property A new patent was filed based on results from study AB12003, which would permit AB Science to retain exclusive rights on the use of masitinib in Prostate Cancer until 2042 Protection Item Duration of protection Status Patent on composition of Patent on composition of matter has
Slide 27: Market
Market The market potential is significant with 125,000 eligible patients in EU and US Estimated number of potential eligible patients Annual cost of drugs registered in Indication Prevalence the indication US Patients EU Patients Sipuleucel T (Provenge) : 93,000 USD Prostate Cancer 113 / 100,0001 E
Slide 28: Q&A
Q&A